Zobel, Emilie H.
Ripa, Rasmus S.
von Scholten, Bernt J.
Rotbain Curovic, Viktor
Kjaer, Andreas
Hansen, Tine W.
Rossing, Peter
Størling, Joachim
Article History
Received: 18 May 2021
Accepted: 1 September 2021
First Online: 17 September 2021
Competing interests
: VRC and JS declare no competing interests. RR, BS, TWH, and PR had shares in Novo Nordisk A/S. EHZ is now an employee of Novo Nordisk A/S but work related to this article was conducted while EHZ was employed by Steno Diabetes Center Copenhagen. BS is now an employee of Novo Nordisk A/S. AK has received consultancy fees from Novo Nordisk. PR has received the following: Consultancy and/or speaking fees (to Steno Diabetes Center Copenhagen) from AbbVie, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, MSD, Novo Nordisk and Sanofi Aventis; Research grants to institution from AbbVie, AstraZeneca and Novo Nordisk.